Emergent BioSolutions Announces Amendment to its Existing Credit Facility
April 30 2024 - 5:26PM
Emergent BioSolutions Inc. (NYSE: EBS) announced that it has
entered into a “Consent, Waiver and Seventh Amendment” to its
existing credit facility.
“In light of this amendment, Emergent now has an extended runway
to execute on our go-forward business plan to stabilize our
financial position,” stated Joe Papa, president and CEO of
Emergent. “Our bank group continues to work with our management
team in a constructive fashion, evidenced by this positive
development.”
On May 1, 2024, Emergent will report its first quarter 2024
financial results via conference call, as well highlight key
business updates, Q1 2024 financial review, and FY 2024 and Q2 2024
guidance.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25
years, we’ve been at work defending people from things we hope will
never happen—so we are prepared just in case they ever do. We
provide solutions for complex and urgent public health threats
through a portfolio of vaccines and therapeutics that we develop
and manufacture for governments and consumers. We also offer a
range of integrated contract development and manufacturing services
for pharmaceutical and biotechnology customers. To learn more about
how we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us on LinkedIn, X,
Instagram, Apple Podcasts and Spotify.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, are forward-looking
statements. We generally identify forward-looking statements by
using words like “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “forecast,” “future,” “goal,” “intend,”
“may,” “plan,” “position,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would,” and similar
expressions or variations thereof, or the negative thereof, but
these terms are not the exclusive means of identifying such
statements. Forward-looking statements are based on our current
intentions, beliefs and expectations regarding future events based
on information that is currently available. We cannot guarantee
that any forward-looking statements will be accurate. Readers
should realize that if underlying assumptions prove inaccurate or
if known or unknown risks or uncertainties materialize, actual
results could differ materially from our expectations. Readers are,
therefore, cautioned not to place undue reliance on any
forward-looking statements. Any forward-looking statement speaks
only as of the date of this press release and, except as required
by law, we do not undertake any obligation to update any
forward-looking statement to reflect new information, events or
circumstances.
There are a number of important factors that could cause our
actual results to differ materially from those indicated by any
forward-looking statements. Readers should consider this cautionary
statement, as well as the risk factors and other disclosures
included in our periodic reports filed with the U.S. Securities and
Exchange Commission, when evaluating our forward-looking
statements.
Investor Contact:Richard S. LindahlExecutive
Vice President, CFOlindahlr@ebsi.com
Media Contact:Assal HellmerVice President,
Communicationsmediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Jul 2023 to Jul 2024